Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2002

View Archived Issues

Antioxidants AEOL-10113 and AEOL-10150 have protective effects on isolated pancreatic islet cells

Oncogene BRAF is mutated in a high proportion of human melanomas

Novel GABA-A/BDZ modulators presented by Neurogen and Lilly at ACS meeting

Synthesis and SAR of new series of CRH1 antagonists reported in Boston

TACE inhibitors presented by Bristol-Myers Squibb at ACS

Compounds with potent and selective caspase-3 inhibitory activity disclosed by Merck Frosst

5-ASA-containing prodrugs for IBD presented at ACS

Aphton files for fast track designation for G17DT in gastric cancer

Gleevec granted priority review for first-line use in early CML

Sepracor and MedPointe to copromote Astelin

SGN-15 enters phase II in advanced ovarian cancer

Transition Therapeutics begins phase I trial of interferon enhancing therapy

Phase III Chronogesic trial placed on partial hold pending trial protocol amendments

BioMarin completes acquisition of Glyko Biomedical

Incara stops patient enrollment in deligoparin trial

Dual dopamine D4 and 5-HT2A receptor antagonists described by Lundbeck

Compounds with utility as 5-HT6 ligands claimed in patent

Boehringer Ingelheim claims telomerase-inhibiting carboxamides

Dr. Reddy's Research Foundation describes antibacterial compounds in patent

Kosan Biosciences describes compounds for gastrointestinal motility disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...